June 14, 2021
Article
Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.
May 27, 2021
The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.
May 24, 2021
TAK-003, from Takeda, is showing slightly improved protection among seropositive participants through its 36-month follow-up.
May 20, 2021
A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.
May 11, 2021
Discriminately affected populations face a wall of hurdles, historic and contextual, in buying into COVID-19 vaccine benefit. What can clinicians and public health officials do to help?
May 10, 2021
The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.
May 05, 2021
New real-world research suggest the vaccine may help provide control of the pandemic virus.
May 03, 2021
A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.
April 22, 2021
New analysis of registry data suggest pregnant persons are not facing particularly worse pregnancy nor neonatal outcomes after mRNA vaccination.
April 16, 2021
